CervoMed is trading 5.4% higher at $2.82 as of 10:47 a.m. ET on September 29, with its September 28 neflamapimod update the clearest potential catalyst. - The company announced a new 50 mg neflamapimod tablet, and the FDA removed the prior drug-exposure limit, allowing greater dosing flexibility in future trials. - CervoMed plans to advance a 100 mg twice-daily regimen. - The release did not explicitly attribute the share-price move to the news.